Biotech and Pharmaceuticals Life Sciences

More

  • LONDON, July 28- AstraZeneca's chief executive believes a rival could spot the growing value of its drug pipeline but declined to say on Thursday if the group was likely to be a takeover target once more, two years after seeing off a bid from Pfizer. Citi analyst Andrew Baum suggested in a note this week that AstraZeneca's biotech expertise and advanced...

  • CAMBRIDGE, Mass. _ Ariad Pharmaceuticals Inc. on Thursday reported second-quarter net income of $109.8 million, after reporting a loss in the same period a year earlier. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share. This story was generated by Automated Insights using data from Zacks...

  • NEW YORK— Bristol-Myers Squibb Co. on Thursday reported second-quarter net income of $1.17 billion, after reporting a loss in the same period a year earlier. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 67 cents per share. Five analysts surveyed by Zacks expected $4.63 billion.

  • WASHINGTON _ Vanda Pharmaceuticals Inc. on Wednesday reported a loss of $4.6 million in its second quarter. On a per-share basis, the Washington- based company said it had a loss of 11 cents. Keywords: Vanda Pharmaceuticals, Earnings Report.

  • LONDON, July 27- GlaxoSmithKline has bought global rights to an experimental drug from Johnson& Johnson for up to 175 million pounds, raising its bet on a new generation of biotech medicines for severe asthma. The British drugmaker recently launched Nucala, its first injectable biological asthma drug, and is looking for additional treatments to help more...

  • BOTHELL, Wash. _ Alder BioPharmaceuticals Inc. on Tuesday reported a loss of $38.9 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 75 cents per share. Alder BioPharmaceuticals shares have fallen 11 percent since the beginning of the year.

  • Medical students and members of the public will be able to watch a live hernia surgery in 360-degree virtual reality (VR) later this week.

  • An MRI scan of an Alzheimer patient's brain.

    Research shown at the Alzheimer's Association International Conference suggests people with complex careers may be resistant to the disease.

  • MONTREAL— A Quebec City- based research team has received the green light to begin testing a Zika vaccine on humans in collaboration with U.S.-based partners. The researchers based at Universite Laval are the first in Canada to be authorized by Canada's federal health agency and the U.S. Food and Drug Administration to conduct clinical tests.

  • Venter on killing cancer

    J. Craig Venter, Human Longevity Inc., CEO, on how science is on the verge of finding cancer in its earliest stages.

  • CNBC Pro: Big business of human longevity

    J. Craig Venter, Human Longevity Inc., CEO, discusses how advances in technology could expand human life spans.

  • July 19- Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion. The deal for the tiny Cambridge, Massachusetts- based company comes just at little...

  • Aedes aegypti mosquito, the species which transmits the dengue virus, chikungunya fever and zika

    Utah health officials said a caregiver of an elderly patient who died while infected with Zika is positive for the virus.

  • NEW YORK, July 14- Martin Shkreli, the former pharmaceutical executive who last year became a lightning rod for criticism of soaring prescription drug prices, is now scheduled to go on trial in June 2017 in the U.S. government's securities fraud case against him. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against...

  • NEW YORK, July 14- Martin Shkreli, the former pharmaceutical executive who became a lightning rod for criticism of soaring prescription drug prices last year, is now scheduled to go on trial in June 2017 in the U.S. government securities fraud case. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli and Evan...

  • NEW YORK, July 14- A federal judge on Thursday scheduled a trial for June 2017 in the U.S. government's securities fraud case against former pharmaceutical executive Martin Shkreli, who became a lightning rod last year for criticism of soaring prescription drug prices. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case...

  • District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli and Evan Greebel, a former lawyer for Retrophin Inc, a biopharmaceutical company which Shkreli headed until 2014..

  • July 12- Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49.. Prevnar has been buoying Pfizer's revenue, helping the company beat Wall Street estimates. The Prevnar range of products grossed annual sales of $6.25 billion in 2015, up 40 percent from a year...

  • Elizabeth Holmes

    U.S. regulators have banned Elizabeth Holmes, the chief executive of Theranos, from owning or operating a laboratory for at least two years.

  • *Accord with Walter Reed Army Institute of Research. PARIS/ LONDON, July 6- French drugmaker Sanofi said on Wednesday it had struck a research and development deal with the U.S. Army to speed up the development of a vaccine against the mosquito-borne Zika virus. The tie-up with the Walter Reed Army Institute of Research in the United States gives Sanofi access to a...